Search Result
Results for "
bone loss
" in MedChemExpress (MCE) Product Catalog:
1
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-18664
-
PFI-4
1 Publications Verification
|
Epigenetic Reader Domain
|
Cancer
|
|
PFI-4 (compound 11) is a potent and highly selective BRPF1 Bromodomain (BRPF1B) inhibitor, with an IC50 of 172 nM. PFI-4 can be used to explore the functional mechanisms of the HBO1/BRPF1 complex and to study bone loss and osteolytic malignant bone lesions .
|
-
-
- HY-N7501
-
|
|
Others
|
Metabolic Disease
Inflammation/Immunology
|
|
Isoformononetin is an analog of Daidzein (HY-N0019) and has immunoprotective effects. Isoformononetin inhibits the differentiation of Th17 and B-cells lymphopoesis to promote osteogenesis in estrogen-deficient bone loss conditions .
|
-
-
- HY-N9331
-
|
Cimicidanol-3-O-β-d-xyloside
|
Others
|
Metabolic Disease
|
|
Cimicifugoside H-1, a cyclolanostanol xyloside, is a major constituent of C. foetida L. extract. Cimicifugoside H-1 inhibits bone resorption and ovariectomy-induced bone loss .
|
-
-
- HY-103352
-
|
L-235
|
Cathepsin
|
Metabolic Disease
|
|
L-006235 (L-235) is a potent, selective, reversible and orally active inhibitor of cathepsin K, with an IC50 of 5 nM in bone resorption assay. L-006235 shows selectivity for cathepsin K (Ki=0.2 nM) over cathepsin B, cathepsin L, and cathepsin S (Ki=1, 6, and 47 μM, respectively). L-006235 can reduce collagen degradation and prevent bone loss .
|
-
-
- HY-135594
-
|
|
Estrogen Receptor/ERR
|
Metabolic Disease
|
|
4'-Raloxifene-β-D-glucopyranoside, a metabolite of Raloxifene, is a benzothiophene glucuronidated at the 4' postion. 4'-Raloxifene-β-D-glucopyranoside is a selective and orally active estrogen receptor antagonist. 4'-Raloxifene-β-D-glucopyranoside can be used for inhibiting bone loss and resorption, and lowering lipid levels. 4'-Raloxifene-β-D-glucopyranoside, example 5, is extracted from patent US5567820A .
|
-
-
- HY-123370
-
|
|
Proton Pump
|
Metabolic Disease
Cancer
|
|
FR-167356 is a potent, orally active and selective vacuolar ATPase inhibitor with IC50 values of 170, 220, 370, and 1200 nM for osteoclast plasma membranes, macrophage microsomes, renal brush border membranes, and liver lysosomal membranes, respectively. FR-167356 inhibits bone resorption and ovariectomy-induced bone loss .
|
-
-
- HY-123310
-
|
|
Androgen Receptor
|
Cancer
|
|
JNJ-26146900 is a potent and orally active androgen receptor antagonist with a Ki value of 400nM for rat AR. JNJ-26146900 is a nonsteroidal androgen receptor (AR) ligand. JNJ-26146900 reduces prostate tumor size and prevents bone loss. JNJ-26146900 can be used in research of cancer .
|
-
-
- HY-116198
-
|
|
15-PGDH
|
Metabolic Disease
|
|
15-PGDH-IN-2 (Compound 2) is a 15-PGDH inhibitor with an IC50 value of 0.274 nM. 15-PGDH-IN-2 can be used in research on hair loss, bone formation, gastric ulcer healing, and dermal wound healing .
|
-
-
- HY-113230
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Galactosylhydroxylysine is a component of bone collagen produced by post-translational glycosylation of hydroxylysine. Galactosylhydroxylysine is released during bone resorption and has been shown to be elevated in metabolic bone loss .
|
-
-
- HY-113230B
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Galactosylhydroxylysine hydrochloride is a component of bone collagen produced by post-translational glycosylation of hydroxylysine. Galactosylhydroxylysine hydrochloride is released during bone resorption and has been shown to be elevated in metabolic bone loss .
|
-
-
- HY-146056
-
|
|
Others
|
Others
|
|
Compounds, as a new type of bone morphogenetic protein-2 up regulator, can not only correct the bone loss in patients, but also have a wide range of clinical applicability.
|
-
-
- HY-122359B
-
|
L-Centchroman fumarate
|
Estrogen Receptor/ERR
|
Others
|
|
Levormeloxifene (fumarate) is a stable salt form of Levormeloxifene. Levormeloxifene (fumarate) is an estrogen receptor modulator that plays an important role in prevention of postmenopausal bone loss .
|
-
-
- HY-N1485
-
|
Astramembrangenin; Cyclosieversigenin
|
|
|
|
Cycloastragenol (Astramembrangenin), the active form of astragaloside IV, has anti-oxidant, anti-inflammatory, anti-aging, anti-apoptotic, and cardiovascular protective effects. Cycloastragenol is a potent telomerase activator and can lengthen telomeres. Cycloastragenol alleviates age-related bone loss and improves bone microstructure and biomechanical properties .
|
-
-
- HY-N2119
-
|
|
|
|
|
Sciadopitysin is a type of biflavonoids in leaves from ginkgo biloba . Sciadopitysi inhibits RANKL-induced osteoclastogenesis and bone loss by inhibiting NF-κB activation and reducing the expression of c-Fos and NFATc1 .
|
-
-
- HY-B1246
-
|
|
Bacterial
Proton Pump
|
Infection
|
|
Thonzonium bromide is an antibacterial agent that is structurally similar to Farnesol (HY-Y0248A). Thonzonium bromide is also a monocationic surface-active agent, which inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Thonzonium bromide inhibits proton transport in a dose-dependent manner (EC50=69 μM) .
|
-
-
- HY-P2612
-
|
|
TNF Receptor
|
Others
|
|
WP9QY, TNF-a Antagonist, TNF-a Antagonist is a biological active peptide. (This cyclic peptide is designed to mimic the most critical tumor necrosis factor (TNF) recognition loop on TNF receptor I. It prevents interactions of TNF with its receptor. This TNF antagonist is a useful template for the development of small molecular inhibitors to prevent both inflammatory bone destruction and systemic bone loss in rheumatoid arthritis.)
|
-
-
- HY-121149
-
|
3-Hydroxytamoxifen
|
Estrogen Receptor/ERR
Apoptosis
|
Cancer
|
|
Droloxifene, a Tamoxifen derivative, is an orally active and selective estrogen receptor modulator. Droloxifene shows antiestrogenic and anti-implantation effects. Droloxifene induces p53 expression and apoptosis in MCF-7 cells. Droloxifene prevents bone loss in ovariectomized rats .
|
-
-
- HY-N7501S
-
|
|
Isotope-Labeled Compounds
|
Inflammation/Immunology
|
|
Isoformononetin-d3 is the deuterium labeled Isoformononetin (HY-N7501). Isoformononetin is an analog of Daidzein (HY-N0019) and has immunoprotective effects. Isoformononetin inhibits the differentiation of Th17 and B-cells lymphopoesis to promote osteogenesis in estrogen-deficient bone loss conditions .
|
-
-
- HY-N1993
-
|
|
|
|
|
5-Methyl-7-methoxyisoflavone is a non-steroidal anabolic isoflavone. 5-Methyl-7-methoxyisoflavone shows potency increasing muscle mass and endurance. 5-Methyl-7-methoxyisoflavone can be used for fat loss, increase vitality and muscle gain besides the maintenance of low cholesterol level and strengthen bones .
|
-
-
- HY-13738
-
Raloxifene
Maximum Cited Publications
9 Publications Verification
Keoxifene; LY156758 free base; LY139481
|
Estrogen Receptor/ERR
|
Cancer
|
|
Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research .
|
-
-
- HY-P99590
-
|
ACE-011
|
TGF-β Receptor
|
Inflammation/Immunology
Cancer
|
|
Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions .
|
-
-
- HY-135595
-
|
|
Estrogen Receptor/ERR
Drug Metabolite
|
Metabolic Disease
|
|
6-Raloxifene-β-D-glucopyranoside, a derivative of Raloxifene, is a benzothiophene glucuronidated at the 6' postion. 6-Raloxifene-β-D-glucopyranoside is a selective and orally active estrogen receptor antagonist. 6-Raloxifene-β-D-glucopyranoside can be used for inhibiting bone loss and resorption, and lowering lipid levels. 6'-Raloxifene-β-D-glucopyranoside, compound Ia, is extracted from patent US5567820A .
|
-
-
- HY-15028
-
|
ATB-346
|
COX
Apoptosis
|
Inflammation/Immunology
|
|
Otenaproxesul (ATB-346), an orally active non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase-1 and 2 (COX-1 and 2). Otenaproxesul possesses antiinflammatory and antinociceptive activities .
|
-
-
- HY-18252
-
|
TA1790
|
Phosphodiesterase (PDE)
NO Synthase
Endogenous Metabolite
|
Cardiovascular Disease
Endocrinology
|
|
Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .
|
-
-
- HY-18252A
-
|
TA1790 dibenzenesulfonate
|
Phosphodiesterase (PDE)
NO Synthase
Endogenous Metabolite
|
Cardiovascular Disease
Endocrinology
|
|
Avanafil (TA-1790) dibenzenesulfonate is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis .
|
-
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P2612
-
|
|
TNF Receptor
|
Others
|
|
WP9QY, TNF-a Antagonist, TNF-a Antagonist is a biological active peptide. (This cyclic peptide is designed to mimic the most critical tumor necrosis factor (TNF) recognition loop on TNF receptor I. It prevents interactions of TNF with its receptor. This TNF antagonist is a useful template for the development of small molecular inhibitors to prevent both inflammatory bone destruction and systemic bone loss in rheumatoid arthritis.)
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99590
-
|
ACE-011
|
TGF-β Receptor
|
Inflammation/Immunology
Cancer
|
|
Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N7501
-
-
-
- HY-N9331
-
-
-
- HY-113230B
-
-
-
- HY-18252
-
|
TA1790
|
Cardiovascular Disease
Structural Classification
Natural Products
Classification of Application Fields
Source classification
Endogenous metabolite
Disease Research Fields
Endocrinology
|
Phosphodiesterase (PDE)
NO Synthase
Endogenous Metabolite
|
|
Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .
|
-
-
- HY-113230
-
-
-
- HY-18252A
-
|
TA1790 dibenzenesulfonate
|
Cardiovascular Disease
Structural Classification
Natural Products
Classification of Application Fields
Source classification
Endogenous metabolite
Disease Research Fields
Endocrinology
|
Phosphodiesterase (PDE)
NO Synthase
Endogenous Metabolite
|
|
Avanafil (TA-1790) dibenzenesulfonate is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis .
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-N7501S
-
|
|
|
Isoformononetin-d3 is the deuterium labeled Isoformononetin (HY-N7501). Isoformononetin is an analog of Daidzein (HY-N0019) and has immunoprotective effects. Isoformononetin inhibits the differentiation of Th17 and B-cells lymphopoesis to promote osteogenesis in estrogen-deficient bone loss conditions .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
